Browse studies

Find your next paid study

6 recruiting studies matching your filters

Phase I Trial of IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors

Background: Myeloid cells are a type of immune cell found in most tumors. Interleukin 12 (IL-12) is a protein that helps the immune system kill tumor cells. R…

Relapsed Solid Tumor MalignanciesRefractory Solid Tumor Malignancies

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07672483

Natural History and Biospecimen Acquisition Study for Children and Adults With Rare Solid Tumors

Background: Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small p…

Malignant Solid TumorsOther Neoplasms Solid TumorsPediatric Solid Tumor+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT03739827

Phase 1

A Phase 1/2 Clinical Trial of the Novel Topoisomerase I Inhibitor PEEL-224 as a Single Agent and in Combination With Vincristine and Temozolomide in Children With Refractory, Progressive or Relapsed Solid Tumors

The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vi…

Refractory Solid TumorsRelapsed Solid TumorsRelapsed Neuroblastoma+3 more

Estimated

~$10 – $7,500

Theodore LaetschNCT06721689

Phase 1

ANGIO-A: Safety and Tolerability of Oral Cyclophosphamide and Sorafenib With Intravenous Bevacizumab With the Addition of Atezolizumab in Pediatric Solid Tumor Patients

This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamid…

Refractory Solid TumorHepatocellular CarcinomaMalignant Solid Tumor+3 more

Estimated

~$10 – $6,250

St. Jude Children's Research HospitalNCT05468359

Phase 1

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.

Refractory Solid Tumors

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06006273

Phase 1

Open Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors

Subjects will undergo baseline evaluation and an assessment of extent of disease. Subjects in Part 1 (Dose Escalation) will receive escalating doses of CB-03-…

Advanced Refractory Solid TumorsSubjects Considered Likely to Respond to CB-03-10

Estimated

~$10 – $8,750

Cosmo Technologies LtdNCT03863145